FATE Fate Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
16:18
Jan 14
Jan 14
Fate Therapeutics below cash, clinical catalyst 2026
The author argues Fate Therapeutics is a potential multi-bagger, trading at $1 and below its cash value with a decent pipeline ahead of similar biotech peers. The catalyst is progress in clinical trials, with 2026 possibly being the company's year. The main risk is that the upside depends on clinical trial progress that may not materialize.
MED
About FATE Investor Commentary
Across the available history and selected sources, Buzzberg tracks FATE (Fate Therapeutics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/gtownguy123.